Minnesota Multidisciplinary Vasculitis Program

Front Row L to R: S. Thaker, S. Reule, M. Rheault, H. Boyer, C. Fanola, D. Pearson, H. Muster
Back Row L to R: P. Nachman, S. Rajala, L. Ghazi, M. Beard, P. Fazeli, K. Woerner, D. Mueller, M. Pritzker, P. Ardnt
Mission
To provide patients with systemic inflammatory disease or vasculitis with cutting-edge, individualized, comprehensive and integrated multidisciplinary care and access to clinical trials.
Covered Diseases
- Systemic vasculitis:
- Small vessel vasculitis (ANCA-vasculitis, Anti-GBM disease, IgA Vasculitis)
- Medium vessel vasculitis
- Large vessel vasculitis
- Systemic Lupus Erythematosus
Goals
- Provide patients with complex systemic diseases with multidisciplinary care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with complex systemic diseases.
Multidisciplinary Team
Cardiology
Dermatology
Nephrology
- Patrick Nachman, MD
- Milind Junghare, MD
- Surabhi Thakar, MD
- Katti Woerner, MD
- Michelle Rheault, MD (Pediatrics)
Otolaryngology (ENT)
Pulmonary
Rheumatology
Ongoing Clinical Trials
ANCA Vasculitis
Coming soon!
SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Phase 2 Trial
Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects With Systemic Lupus Erythematosus
Principal Investigator
Study Coordinator
Julie Scherber
sche0245@umn.edu
Phase 3 Trial
A Two-year, Phase III Randomized, Double-blind, Parallel-group, Placebo-controlled Trial to Evaluate the Safety, Efficacy, and Tolerability of 300 mg s.c. Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis
Principal Investigator
Co-Investigators
Study Coordinator
Elizabeth Miller, RN, BAN, PHN, CCRC
mill7440@umn.edu
Phase 3 Trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)
Principal Investigator
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu